ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Two Drugs Slow Progress Of Metastatic Prostate Cancer

June 29, 2001

Institutions Fail To Credit NIH when Patenting discoveries, HHS Says

July 15, 1994

M.D. Anderson Wins Nearly $54 Million in ARRA Funding From NIH

November 6, 2009

Progress Measures “Adequate,” Committee Says; Suggestions Include New Death Measure

August 12, 1988

Kimes Calls Headline On DRG ‘Exaggerated Negativity’ In Letter

April 5, 1991

GA Draft Report Lukewarm On Cancer Survival Improvement; NCI Says It Is “Opinion, Not Fact”

April 3, 1987